The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker

As China's regulators renew moves to encourage the development of pediatric medicines, indication expansion may give health players a new growth engine, despite remaining policy challenges and lingering market uncertainties.

The CEO of South Korea's Hanmi Pharm shares experiences around licensing deals and turning around returned assets, identifying "great opportunities" in the near term for the country's pharma and biotech sectors as global partners continue to hunt for novel products and technologies.

Encouraging new data for Spectrum/Hanmi’s poziotinib presented at ESMO may increase the chances of approval for the pan-HER inhibitor as a possible first-line therapy for NSCLC with the HER2 exon 20 insertion mutation, although the patient population is limited.